TESAMORELIN / IPAMORELIN

Tesamorelin, an analog of growth hormone releasing hormone, has demonstrated the ability to elevate IGF-1 levels by an average of 181 micrograms/liter. It binds to and activates human GHRH receptors with a potency akin to endogenous GHRH. Beyond these effects, Tesamorelin offers a range of benefits, including nootropic properties and the reduction of triglycerides. Recent research has revealed its capacity to decrease carotid intima media thickness (cIMT), visceral adipose tissue (VAT), and C-reactive proteins (CRP).

Ipamorelin is recognized as a selective GH-Secretagogue and an agonist for ghrelin receptors. Its ghrelin stimulation potency is comparable to GHRP6 but with fewer appetite-stimulating properties. Notably, it distinguishes itself by avoiding the release of significant volumes of cortisol, acetylcholine, prolactin, and aldosterone, setting it apart as the first selective GH-Secretagogue. The combination of Ipamorelin and Tesamorelin offers the potential for enhanced effects, leveraging their distinct mechanisms to stimulate the growth hormone axis synergistically.

Ipamorelin and Tesamorelin demonstrate minimal side effects, exhibiting low oral and excellent subcutaneous bioavailability in mice. These peptides are available for purchase at Paramount Peptides for educational and scientific research purposes only. Interested buyers should ensure they are licensed researchers before acquiring Ipamorelin and Tesamorelin.